• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyrimidines Pyrrolo[2,3-d]pyrimidines

Recent Advances in the Study of 4-Bromo-7H-pyrrolo[2,3-d]pyrimidin-2-amine (CAS: 848694-32-6)

The compound 4-Bromo-7H-pyrrolo[2,3-d]pyrimidin-2-amine (CAS: 848694-32-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This heterocyclic compound, belonging to the pyrrolopyrimidine class, serves as a versatile building block for the synthesis of various biologically active molecules. Recent studies have highlighted its role as a key intermediate in the development of kinase inhibitors, particularly those targeting oncogenic signaling pathways.

One of the most notable advancements in the study of this compound is its incorporation into the synthesis of novel JAK (Janus kinase) inhibitors. Researchers have demonstrated that derivatives of 4-Bromo-7H-pyrrolo[2,3-d]pyrimidin-2-amine exhibit potent inhibitory activity against JAK family kinases, which are implicated in inflammatory diseases and hematologic malignancies. A 2023 study published in the Journal of Medicinal Chemistry reported the optimization of this scaffold to improve selectivity and pharmacokinetic properties, leading to the identification of promising preclinical candidates.

In addition to its applications in kinase inhibitor development, recent investigations have explored the use of 4-Bromo-7H-pyrrolo[2,3-d]pyrimidin-2-amine as a precursor for fluorescent probes. A team at MIT developed a series of pyrrolopyrimidine-based probes that exhibit strong fluorescence in the visible spectrum, enabling real-time imaging of cellular processes. This innovation opens new avenues for studying intracellular signaling dynamics and drug-target interactions.

The synthetic accessibility of 4-Bromo-7H-pyrrolo[2,3-d]pyrimidin-2-amine has also been improved through recent methodological developments. A 2024 publication in Organic Letters described a novel one-pot synthesis approach that significantly reduces the number of steps required to produce this compound while maintaining high yield and purity. This advancement is particularly valuable for scaling up production for pharmaceutical applications.

From a safety and toxicological perspective, recent preclinical studies have provided important insights into the pharmacological profile of compounds derived from this scaffold. While showing generally favorable safety indices, structure-activity relationship studies have identified specific modifications that can further enhance the therapeutic window. These findings are guiding the design of next-generation derivatives with improved efficacy and reduced off-target effects.

Looking forward, the versatility of 4-Bromo-7H-pyrrolo[2,3-d]pyrimidin-2-amine continues to inspire innovative applications across multiple therapeutic areas. Current research efforts are exploring its potential in targeting protein-protein interactions, modulating epigenetic enzymes, and developing covalent inhibitors. The compound's unique structural features and demonstrated biological relevance ensure its ongoing importance in medicinal chemistry research.

• 2891510-79-3(4-bromo-7H-pyrrolo[2,3-d]pyrimidine-2,5,6-d3)
• 89280-82-0(6-Bromo-7H-pyrrolo[2,3-d]pyrimidine)
• 889939-42-8(4-Bromo-7H-pyrrolo[2,3-D]pyrimidine)
• 1161763-14-9(4-bromopyrido[2,3-d]pyrimidine)
• 2891517-86-3(4-bromopyrido[2,3-d]pyrimidine-2,5,6,7-d4)
• 1557521-99-9(6-bromo-7H-pyrrolo[2,3-d]pyrimidin-2-amine)
• 2138523-28-9(7-bromopyrido2,3-dpyrimidin-2-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)